GlobeNewswire

Datameer Achieves Advanced Technology Partner Status in the Amazon Web Services Partner Network and Launches Datameer Express on AWS Marketplace

Dela

SAN FRANCISCO, July 11, 2018 (GLOBE NEWSWIRE) -- Datameer, a leader in big data management for analytics, is pleased to announce that it has achieved Advanced Technology Partner status in the Amazon Web Services (AWS) Partner Network (APN). In addition, Datameer Express is now available on AWS Marketplace, allowing organizations to leverage AWS to simplify their management of data for analytics. Datameer Express provides the accessibility, flexibility, and simplicity of AWS and allows enterprises to be up and running in less than 30 minutes.

Datameer Express is an analytics data management platform that natively leverages AWS to deliver faster time to insight without the need to code or integrate disparate tools. Datameer covers the full data lifecycle from integration to preparation to exploration, and works with any data source, and with any Business Intelligence (BI) or data science tool. It simplifies and accelerates the time-consuming, cumbersome process of turning complex, multi-source data into valuable business-ready information to drive greater business agility. Availability of Datameer Express on AWS Marketplace helps enterprises eliminate the burden of turning complex and dispersed data into business-ready information by leveraging Datameer and migrate more workloads to AWS services like Amazon Simple Storage Service (Amazon S3) and Amazon Elastic Compute Cloud (Amazon EC2).

"We're excited to continue advancing our relationship with AWS and give customers access to Datameer directly from AWS Marketplace, where leading global organizations are modernizing and transforming their analytics infrastructures," said Claudine Lagerholm, Vice President, Strategic Partnerships at Datameer. "We're proud to be an APN Advanced Technology Partner as more of our customers continue moving to the cloud. Making Datameer available on AWS Marketplace simplifies the deployment and procurement process for companies looking to leverage all their data for faster, better decision-making, and AWS delivers the cost-effectiveness, agility, and flexibility they need."

Datameer Express on AWS
Datameer Express takes the rich data preparation, integration and exploration features of Datameer, and packages it into an easy deployment and consumption model on AWS. Datameer Express works with key AWS services to provide a higher level streamlined and secure platform to create and manage powerful data pipelines to fuel cloud-based analytics. Datameer Express can consume data from Amazon S3, Amazon Redshift, Amazon Aurora and other cloud data sources, integrate with on-premises data sources, and create result sets that can be delivered into Amazon Redshift and other cloud data warehouses, or consumed by Amazon Athena and Amazon QuickSight.

Datameer Express enables companies to empower business analysts to take control and deliver their own personalized analytic data pipelines for any analytics initiative. It facilitates faster, agile data pipelines to feed cloud data warehouses for faster, expandable analytics, derive more value from Amazon S3 data lakes, or drive new innovations in machine learning and artificial intelligence.

Pricing and Availability
Pricing for Datameer Express, which is available immediately, offers hourly and annual pricing models starting at $4.79 per hour. Datameer will be at AWS Summit New York, July 17 at Jacob K. Javits Convention Center (8:00am - 5:00pm). AWS Global Summits are free events designed to bring together the cloud computing community to connect, collaborate, and learn about AWS.

About Datameer
Datameer is changing the way companies do business by enabling them to get value and insights from their data at the speed of thought to make better, more trustworthy decisions and drive better business outcomes. Datameer offers a unified way to simplify the time-consuming, cumbersome process of turning complex, multi-source data into valuable, business-ready information in a matter of minutes and hours, rather than weeks or months. Leading global organizations, including Citibank, Royal Bank of Canada, Aetna, Optum, HSBC, National Instruments, Vivint and more use our secure and scalable enterprise-grade platform to streamline and simplify data integration, preparation and exploration so subject matter experts can leverage trusted data to cultivate innovation, creativity and efficiency for competitive advantage. Learn more at www.datameer.com and follow us on Twitter at @Datameer.

Samantha Leggat
samantha.leggat@datameer.com



This announcement is distributed by Nasdaq Corporate Solutions on behalf of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely responsible for the content, accuracy and originality of the information contained therein.
Source: Datameer via Globenewswire

Om

GlobeNewswire



Följ GlobeNewswire

Abonnera på våra pressmeddelanden.

Senaste pressmeddelandena från GlobeNewswire

Immunicum AB (publ) Announces Upcoming Investor Events in January22.1.2019 08:30Pressmeddelande

Press Release 22 January 2019 Immunicum AB (publ) Announces Upcoming Investor Events in January Immunicum AB (publ; IMMU.ST) announced today that Carlos de Sousa, CEO of Immunicum, and other members of the management team will present at upcoming investor conferences in January. Biomed Investor Event by Invest Securities Date: January 22, 2019 Venue: Les Salons Hoche, 9 Avenue Hoche, Paris, France Redeye Fight Cancer Seminar Date: January 22, 2019 Presentation Time: 11.15 am CET Panel: 11.25 am CET Venue: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Date: January 29, 2019 Presentation Time: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Venue: Medicon Village, Scheelevägen 2, Lund, Sweden For more information, please contact: Carlos de Sousa, CEO, Immunicum Telephone: +46 (0) 31 41 50 52 E-mail: info@immunicum.com Michaela Gertz, CFO, Immunicum Telephone: +46 70 926 17 75 E-mail: ir@immunicum.com Media Relations Gretchen Schweitzer an

Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari22.1.2019 08:30Pressmeddelande

Pressmeddelande 22 januari 2019 Immunicum AB (publ) meddelar idag kommande presentationstillfällen under januari Immunicum AB (publ; IMMU.ST) meddelar idag att Immunicums VD, Carlos de Sousa och andra medlemmar av ledningsgruppen kommer presentera vid följande investerarevent under januari. Biomed Investor Event by Invest Securities Datum: 22 januari 2019 Plats: Les Salons Hoche, 9 Avenue Hoche, Paris, France RedEye Fight Cancer Seminar Datum: 22 januari 2019 Presentationstid: 11.15 am CET Panel: 11.25 am CET Plats: Master Samuelsgatan 42, Stockholm, Sweden Aktiespararna - Stora Aktiedagen Datum: 29 januari 2019 Presentationstid: 8.30 - 9.00 am CET Panel: "Samtal om cancerbekämpning", 10:50 am CET Plats: Medicon Village, Scheelevägen 2, Lund, Sweden För ytterligare information kontakta: Carlos de Sousa, VD, Immunicum Telefon: +46 (0) 31 41 50 52 E-post: info@immunicum.com Michaela Gertz, Finanschef, Immunicum Telefon: +46 (0) 70 926 17 75 E-post: ir@immunicum.com Media Relations Gretch

Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Pressmeddelande 21 januari 2019 Immunicum AB (publ) meddelar att resultaten från den kliniska fas I/II-studien med ilixadencel vid långt framskriden levercancer publicerats i Frontiers in Oncology Immunicum AB (publ; IMMU.ST) meddelar idag att den slutliga analysen av data från den undersökande kliniska studien med ilixadencel hos patienter med långt framskriden levercancer har publicerats i tidskriften, Frontiers in Oncology . Dessa data bekräftar de tidigare meddelade positiva egenskaperna gällande säkerhet och tolerabilitet för ilixadencel, både när det ges som enda behandling och i kombination med första linjens standardbehandling, sorafenib. Dessutom påvisades ökade nivåer av tumörspecifika CD8+ T-celler i cirkulerande blod för en majoritet av de utvärderbara patienterna, vilket indikerar ett systemiskt immunologiskt svar. De fullständiga resultaten ger ytterligare insikter om ilixadencels verkningsmekanism, tecken på klinisk effekt samt viktig information som kommer att vara vägl

Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology21.1.2019 08:30Pressmeddelande

Press Release 21 January 2019 Immunicum AB (publ) Announces Publication of Phase I/II Clinical Trial Results of Ilixadencel in Advanced Hepatocellular Carcinoma in Frontiers in Oncology Immunicum AB (publ; IMMU.ST) announced today that the final data analysis from the exploratory clinical study of ilixadencel in patients with advanced hepatocellular carcinoma (HCC) has been published in the journal, Frontiers in Oncology . The data confirms previously communicated positive safety and tolerability of ilixadencel when administered both alone and in combination with current first-line standard of care, sorafenib. In addition, the data demonstrate an increased frequency of tumor-specific CD8+ T cells in circulating blood for a majority of evaluable patients, indicating a systemic immune response. The complete results provide further insight on ilixadencel's mode of action, signs of clinical activity and important information that will guide the next stage of clinical development. As commun

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

Karolinska Development's portfolio company Modus Therapeutics completes enrollment in Phase II study with sevuparin7.1.2019 12:00Pressmeddelande

STOCKHOLM, January 7, 2019. Karolinska Development's portfolio company Modus Therapeutics announces that the patient enrollment has been completed in the Phase II study with sevuparin in patients with sickle cell disease (SCD). The results from the study is expected in mid 2019. Modus Therapeutic's randomized, double blind study contains 140 SCD-patients with Acute Vaso Occlusive Crisis (VOC). It compares intravenously administered sevuparin with placebo. The primary endpoint of the study is the demonstration of a reduced time to resolution of patient's VOC. Clincal sites across Europe and the Middle East took part in the study that was conducted in conjunction with Modus Therapeutics' co development partner Ergomed. SCD has a high unmet medical need as there are currently no approved therapies for VOCs. It is an inherited blood disorder that affects between 90,000 to 100,000 patients in the U.S. and is characterized by severely painful VOCs that lead to organ damage due to a lack of o

I vårt pressrum kan du läsa de senaste pressmeddelandena, få tillgång till pressmaterial och hitta kontaktinformation.

Besök vårt pressrum